ARTICLE | Product Development
Chinks in the armor
What’s next for Celgene in light of mongersen failure, Otezla underperformance
October 28, 2017 4:00 AM UTC
Even with slowing revenues tied largely to a single product and a dearth of launches, Wall Street darling Celgene Corp. had been on an extended tear, growing its share price in excess of 300% since the beginning of 2012.
Clinical and commercial disappointments revealed within a one-week period revealed an unexpected weakness, and will see Celgene Corp. relying more heavily on ozanimod for near-term growth, while drivers of mid- to long-term growth are less certain...
BCIQ Company Profiles